Debbie Rigby takes a look at the latest in research news
Data from the Reducing Use of Sedatives (RedUSe) project involved 150 Australian aged care homes demonstrates that antipsychotic and benzodiazepine dose reduction was not associated with deterioration in neuropsychiatric symptoms, quality of life, or social withdrawal. In fact, dose reduction was associated with small improvements in behaviour, particularly less physically non-aggressive behaviour with both drug groups and verbally agitated behaviour with benzodiazepine reduction.
International Psychogeriatrics, published online 18 June 2020.
An Australian observational study on people with hip osteoarthritis has shown a protective effect on hip pain exacerbation of wearing shoes with a heel height of 2.5cm or more. Wearing shoes with heels was associated with a 50% lower odds of pain exacerbations. A longer duration (>6 hours) was also associated with a lower risk of hip pain exacerbations.
J Clin Med 2020;9(6):1872.
A new position statement supports the 2019 GINA strategy of combination of low dose ICS/fast action bronchodilator to not only treat symptoms, but more importantly the underlying inflammation, protecting patients from preventable asthma attacks. Beta2 agonists increase the severity of asthma through enhanced bronchial hyperresponsiveness and reduced lung function. Overreliance on SABA delays recognition of a potentially life-threatening asthma attack
Journal of Asthma, published online 22 June 2020.
Findings from the ETHOS trial show triple therapy with twice-daily budesonide (at either the 160-μg or 320-μg dose), glycopyrrolate, and formoterol resulted in a lower rate of moderate or severe COPD exacerbations than glycopyrrolate–formoterol or budesonide–formoterol. The incidence of confirmed pneumonia ranged from 3.5 to 4.5% in the groups that included inhaled glucocorticoid use and was 2.3% in the glycopyrrolate–formoterol group.
New Engl J Med, 24 June 2020.